UBD anticorps (N-Term)
Aperçu rapide pour UBD anticorps (N-Term) (ABIN634317)
Antigène
Voir toutes UBD AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- Ubiquitin D antibody was raised against the N terminal of UBD
-
Purification
- Affinity purified
-
Immunogène
- Ubiquitin D antibody was raised using the N terminal of UBD corresponding to a region with amino acids RSKTKVPVQDQVLLLGSKILKPRRSLSSYGIDKEKTIHLTLKVVKPSDEE
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
Ubiquitin D Blocking Peptide, (ABIN5616886), is also available for use as a blocking control in assays to test for specificity of this Ubiquitin D antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of UBD antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- UBD (Ubiquitin D (UBD))
-
Autre désignation
- Ubiquitin D
-
Sujet
- UBD qualifies as a marker for an interferon response in hepatocellular carcinoma and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment. Immunohistochemical studies demonstrated increased UBD expression in HIV-associated nephropathy and in autosomal dominant polycystic kidney disease.
-
Poids moléculaire
- 18 kDa (MW of target protein)
-
Pathways
- Ubiquitin Proteasome Pathway
Antigène
-